InspireMD is Proud to Introduce MGuard Prime(R), InspireMD's new Cobalt Chromium MicroNet(R) Protective Stent System

TCT- WASHINGTON, September 23, 2010 /PRNewswire/ -- InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010. MGuard Prime presents an advanced Co-Cr Design of 80 micron struts along with InspireMD's unique MicroNet(R) Mesh Technology.

MGuard Prime features superior flexibility and excellent deliverability and has found to be comparable to the XIENCE V stent when tested for deliverability through a double curved path model. MGuard Prime is indicated for Primary PCI for STEMI, Saphenous Vein Grafts and ACS with visible thrombus. The new MGuard PRIME is CE Marked and will be available in 2011 in selected territories.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without affecting deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

    Contact details:

    http://www.inspire-md.com

    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    [email protected]

SOURCE InspireMD